Cargando…
Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders
OBJECTIVE: Disease-modifying drugs (DMDs) may alter the immune status and thus increase the susceptibility to coronavirus disease 2019 (COVID-19) in patients with MS or neuromyelitis optica spectrum disorders (NMOSD). However, evidence supporting this notion is currently lacking. In this study, we c...
Autores principales: | Fan, Moli, Qiu, Wei, Bu, Bitao, Xu, Yan, Yang, Huan, Huang, Dehui, Lau, Alexander Y., Guo, Jun, Zhang, Mei-Ni, Zhang, Xinghu, Yang, Chun-Sheng, Chen, Jingshan, Zheng, Pei, Liu, Qiang, Zhang, Chao, Shi, Fu-Dong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286663/ https://www.ncbi.nlm.nih.gov/pubmed/32503092 http://dx.doi.org/10.1212/NXI.0000000000000787 |
Ejemplares similares
-
Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder
por: Chen, Bo, et al.
Publicado: (2017) -
Cortical Thinning and Ventricle Enlargement in Neuromyelitis Optica Spectrum Disorders
por: Tian, De-Cai, et al.
Publicado: (2020) -
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014) -
Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders
por: Li, Xindi, et al.
Publicado: (2017) -
Optical Coherence Tomography Reveals Longitudinal Changes in Retinal Damage Under Different Treatments for Neuromyelitis Optica Spectrum Disorder
por: Zeng, Pei, et al.
Publicado: (2021)